Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

T-DM1 Extends PFS in Heavily Pretreated Advanced Breast Cancer

September 29th 2013

T-DM1 extended progression-free survival compared with "physician's choice of treatment" in women with metastatic HER2-positive breast cancer.

Dr. Nielsen on the Pros and Cons of the Ki67 Assay

September 26th 2013

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.

Dr. Albain on Staging and Biology in Breast Cancer

September 24th 2013

Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses staging versus biology in breast cancer.

Dr. Liu on the Limitations of Radiology in Breast Cancer

September 20th 2013

Minetta Liu, MD, breast cancer specialist, Mayo Clinic, Rochester, Minnesota, discusses the limitations of radiology in metastatic breast cancer treatment.

PAM50 Demonstrates Added Clinical Value in Predicting Recurrence Risk

September 19th 2013

The PAM50 test, designed to determine a risk of recurrence score for patients with breast cancer, adds significant prognostic information to clinical decision making and might be superior to other risk assays.

Dr. Aft on Bisphosphonates for Breast Cancer

September 18th 2013

Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

Dr. Budd on Prior Trastuzumab and Paclitaxel Regimens

September 17th 2013

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses prior treatment with trastuzumab and the effect on two regimens of paclitaxel.

First Generic Version of Capecitabine Gains FDA Approval

September 16th 2013

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

Dr. Lehman on Breast MRI and Mastectomy

September 13th 2013

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses how imaging can guide a women with breast cancer to make treatment decisions.

Dr. Steensma on ODAC's Pertuzumab Decision

September 12th 2013

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen

September 12th 2013

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Suzanne Fuqua on the Interaction Between ER and AR

September 12th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, talks about the interaction between estrogen receptors (ER) and androgen receptors (AR) in patients with breast cancer.

Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer

September 11th 2013

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

FDA Panel Set to Vote on Milestone Neoadjuvant Pertuzumab Combo

September 11th 2013

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.

Dr. Garcia on the Future Role of PARP inhibitors

September 9th 2013

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Rugo Offers Window Into Evolving Views of ER-Positive Disease

September 6th 2013

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

Dr. Finn on the Phase III Trial of Palbociclib for Breast Cancer

September 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Puma Begins Phase III Development of Neratinib in Breast Cancer

September 6th 2013

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

Analyzing the Nuances of Trastuzumab Therapy for HER2-Positive Breast Cancer

September 3rd 2013

Trastuzumab is the clear standard of care for firstline therapy for nearly all HER2-positive breast cancers, and the oncology community has come a long way toward understanding how best to use the drug.

Dr. Mittendorf on Cyclin E as a Target in Breast Cancer

August 29th 2013

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.